TL;DR
- New HIV treatment allows some to stop meds for up to two years.
- 75% maintained viral control after stopping medication.
- Study involved 68 participants in the UK and Denmark.
- Researchers hope for a future cure for HIV.
- ART remains essential for many living with HIV.
In a stunning breakthrough, researchers at Imperial College London have unveiled a new HIV treatment that could allow some patients to stop their daily medication for up to two years. Yes, you heard that right! This revolutionary treatment, made from two broadly neutralising antibodies (bNAbs), is set to change the game for those living with HIV.
During a clinical trial involving 68 participants from the UK and Denmark, individuals whose HIV was already under control with antiretroviral therapy (ART) received either the antibody treatment or a placebo. After a period of medical supervision, many were able to stop their usual medication. And the results? A jaw-dropping 75% of those who received the antibody treatment managed to keep their viral load in check for 20 weeks after halting their ART. Talk about a reason to celebrate!
But wait, there’s more! About half of the participants remained off medication for a full year, while around a quarter maintained viral suppression for an impressive two years. The antibodies, known as 3BNC117-LS and 10-1074-LS, target different parts of the HIV virus, and researchers are optimistic that this could pave the way for a new method of controlling HIV without the need for daily pills.
Professor Sarah Fidler from Imperial College London expressed her excitement, stating, “These results open new possibilities for HIV treatment and bring us closer to our goal of finding a cure.” This is the first time a bNAb-based therapy has shown such significant viral load control in a randomised placebo-controlled trial, marking a pivotal moment in HIV research.
While ART has been a life-saving treatment that allows people living with HIV to lead long, healthy lives, it’s not a cure. The virus can remain dormant in cells and can rebound if treatment is interrupted. However, with new UK surveillance figures showing a decline in new HIV diagnoses from 3,169 in 2023 to 3,043 in 2024, the government is ramping up efforts to end new HIV transmissions by 2030.
This groundbreaking research not only offers hope to those living with HIV but also shines a light on the ongoing need for innovative treatments and the potential for a future where daily medication is a thing of the past. As we celebrate these advancements, let’s continue to advocate for the rights and health of the LGBTQ+ community, ensuring that everyone has access to the care they need.